Revised forecast
Fiscal year ending March 2026 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The main factors were the recognition of a ¥5,893 million loss on valuation of cryptoassets held primarily in the digital asset management business as a decrease in net sales. In the energy business, costs increased due to higher market procurement prices and other factors. The Company also recognized a ¥629 million gain on the sale of shares in an affiliated company in connection with the transfer of all shares of 株式会社ゼロメディカル, but this was insufficient to offset the decline in earnings.
| Item | Details |
|---|---|
| Net Sales | -3,378 |
| Operating profit | -4,266 |
| Ordinary income | -4,960 |
| Profit attributable to owners of the parent | -4,147 |
| Net income per share | -28.97 |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Previous-period results | Net sales: ¥21,129 million; operating loss: ¥1,211 million; ordinary loss: ¥541 million; net loss attributable to owners of the parent: ¥593 million; net loss per share: ¥4.92 (fiscal year ended March 2025) |
| Reason for the revision | The main factors were the recognition of a ¥5,893 million loss on valuation of cryptoassets held primarily in the digital asset management business as a decrease in net sales. In the energy business, costs increased due to higher market procurement prices and other factors. The Company also recognized a ¥629 million gain on the sale of shares in an affiliated company in connection with the transfer of all shares of 株式会社ゼロメディカル, but this was insufficient to offset the decline in earnings. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The main factor was the recognition of a ¥5,893 million loss on valuation of cryptoassets held in the digital asset management business as a decrease in net sales, due to the decline in cryptoasset prices. In addition, costs increased in the energy business because of higher market procurement prices and the impact of product plans under which price pass-through extended into the following fiscal year. Meanwhile, the Company recognized a ¥629 million gain on the sale of shares in an affiliated company as an extraordinary gain in connection with the transfer of all shares of 株式会社ゼロメディカル, but this was insufficient to offset the decline in earnings.